Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Powerful Medical
9. November 2023
3 min to read

Poor Prognosis of Total Culprit Artery Occlusion in Patients Presenting with NSTEMI 

Overview:

Traditional ECG criteria miss nearly one-third of heart attack patients with a fully occluded artery, mislabeling them as “NSTEMI” despite needing urgent care. This retrospective study of 10,000 patients found they face longer treatment delays and nearly double the one-year mortality of “acute” STEMI patients, highlighting the need for better ECG-based risk stratification and faster intervention.

Published In: European Heart Journal
Presented Date: November 9, 2023

Background

The prognosis of STEMI and NSTEMI patients stratified according to invasive angiographic findings of an occluded culprit coronary, i.e., occlusion myocardial infarction (OMI), remains unclear.

This retrospective single-center study aimed to compare the clinical presentation, management, and all-cause mortality of STEMI, NSTEMI-OMI, and NSTEMI-Non-OMI (NSTEMI-NOMI).

Methods

Demographics, clinical and procedural data were pooled for all patients with an index ACS event between January 2011 and May 2021. Patients were classified according to the presence of OMI determined by angiography and troponin. All-cause mortality was compared by Kaplan Meier analysis at 1-year and landmark analysis up to 5 years after the ACS event.

Results

A total of 9,943 patients [64.1 ± 14.2 years, 62.2% males] were included and classified into STEMI (n=507), NSTEMI-OMI (n=685), NSTEMI-NOMI (n=1,535) and MI ruled-out (n=7,216). Median time to coronary angiography (CAG) was 1.4 hours for STEMI compared to 16.3 and 45.8 hours for NSTEMI-OMI and NSTEMI-NOMI, respectively (p<0.001) [Figure 1].

At one year, all-cause mortality occurred in 9.9% of STEMI patients vs. 18.1% of NSTEMI-OMI patients (hazard ratio, 1.84; 95% CI, 1.32 to 2.55; p<0.001) and 7.9% of NSTEMI-NOMI patients (hazard ratio, 0.79; 95% CI, 0.56 to 1.09; p=0.150) [Figure 2]. An unfavorable mortality outcome for NSTEMI-OMI compared to STEMI was maintained in the age and gender-adjusted analyses and landmark analysis beyond 1-year (hazard ratio, 2.59; 95% CI, 1.75 to 3.82; p<0.001).

Conclusion

Despite similar baseline demographics and angiographic findings, patients with NSTEMI-OMI have increased delays to reperfusion and unfavorable short and long-term all-cause mortality compared to STEMI. These findings support the need for more accurate and timely identification of NSTEMI-OMI.



Authors: R Herman, S W Smith, H P Meyers, D T Bertolone, A Leone, K Bermpeis, M Viscusi, M Martonak, J Bahyl, A Demolder, L Perl, W Wojakowski, J Bartunek, E Barbato

Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

AI-Enabled ECG Analysis Improves Diagnostic Accuracy and Reduces False STEMI Activations: A Multicenter U.S. Registry

In a large, multi-center evaluation presented as Late-Breaking Science at the TCT 2025 conference, investigators assessed the diagnostic accuracy of the Queen of Hearts™ AI algorithm for ST-segment elevation myocardial infarction (STEMI) detection in emergency care. The study compared AI-enhanced ECG interpretation against standard triage protocols across three U.S. PCI centers, encompassing more than 1,000 patients who activated emergent reperfusion pathways. Published in JACC: Cardiovascular Interventions, the results demonstrated significantly improved accuracy and reduced false activations when using AI-driven analysis.

Electrocardiographic Diagnostic Possibilities for Atrial Fibrillation Using Artificial Intelligence: Differentiation from Sinus Rhythm and Other Arrhythmias with the Pmcardio App in Covid-19 Patients

This study evaluated how effectively artificial intelligence can detect atrial fibrillation (AF) in COVID-19 patients using ECG analysis. Researchers compared the PMcardio AI application’s performance with that of cardiologists and infectious disease specialists. Among 116 hospitalized COVID-19 patients, PMcardio achieved perfect diagnostic accuracy (sensitivity and specificity of 1.00) for AF detection, matching cardiologists and surpassing infectious disease specialists. The AI’s performance remained consistent across confidence levels, and its severity assessments correlated significantly with rhythm findings. These results highlight AI’s potential to improve arrhythmia detection, streamline care, and reduce unnecessary in-person evaluations during infectious disease outbreaks.

Join over 100,000 healthcare professionals who are already taking advantage of AI